Comparative effects of recombinant human brain natriuretic peptide and dobutamine on acute decompensated heart failure patients with differsent blood BNP levels

BMC Cardiovascular Disorders

Hong-Yin Niu¹  Min Pan²  Xiao-Hong Yu²  Yong Gu²  Jian-Hua Zhu²  Hai-Yan Pan² 

[1] Department of Echocardiography, Affiliated Hospital of Nantong University, Jiangsu, China;Department of Cardiology, Affiliated Hospital of Nantong University, and Institute of Cardiovascular Research, Nantong University, Jiangsu 226001, China

关键词: Dobutamine;    Recombinant human brain natriuretic peptide;    Acute decompensated heart failure;   

Others  :  855308
DOI  :  10.1186/1471-2261-14-31

 received in 2013-12-15, accepted in 2014-02-26,  发布年份 2014

【 摘 要 】

Background

Recombinant human B-type natriuretic peptide (rhBNP) has been indicated for the treatment of acute decompensated heart failure (ADHF). However, the therapeutic efficacy of intravenous rhBNP is not always satisfactory in patients with extremely high blood BNP levels. In this study, we evaluated the effects of rhBNP on patients with different BNP levels.

Methods

One hundred and five patients with ADHF whose left ventricular ejection fraction (LVEF) was <40%, were assigned to a high BNP group (BNP ≤ 3000 pg/mL) or an extra-high BNP group (BNP > 3000 pg/mL) , depending on their admission plasma BNP levels. Each group was then subdivided into rhBNP or dobutamine subgroups according to intravenous administration with either rhBNP or dobutamine for 24-72h. In the high BNP group, 58 patients were randomized to subgroup rhBNP (n = 28) and subgroup dobutamine (n = 30). In the extra-high BNP group, 47 patients were randomized to subgroup rhBNP (n = 24) and subgroup dobutamine (n = 23). The effects of rhBNP and dobutamine on patients in the high and extra-high BNP groups were compared.

Results

In the high BNP group, rhBNP was more efficient than dobutamine at improving NYHA classification (P < 0.05), decreasing plasma BNP levels (P < 0.05), increasing LVEF (P < 0.05), and reducing hospital length of stay (P < 0.05). However, rhBNP displayed no superior therapeutic efficacy to dobutamine in the extra-high BNP group. Adverse cardiovascular events in patients treated with rhBNP were similar to adverse events in patients treated with dobutamine in both the high and extra-high BNP groups.

Conclusions

rhBNP was more efficient than dobutamine at improving heart function in patients with ADHF when plasma BNP was ≤3000 pg/mL. However, rhBNP treatment showed no advantages over dobutamine when plasma BNP reached extremely high levels (>3000 pg/mL).

Trial registration

ClinicalTrials.gov Identifier:NCT01837849.

【 授权许可】

   
2014 Pan et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Leier CV, Unverferth DV: Drugs five years later: dobutamine. Ann Intern Med 1983, 99:490-496.
• [2]Arora S, Clarke K, Srinivasan V, Gradman A: Effect of nesiritide on renal function in patients admitted for decompensated heart failure. QJM 2007, 100:699-706.
• [3]Colucci WS: Nesiritide for the treatment of decompensated heart failure. J Card Fail 2001, 7:92-100.
• [4]Nieminen MS, Böhm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, Hasin Y, Lopez-Sendon J, Mebazaa A, Metra M, Rhodes A, Swedberg K, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie MR, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth OA, Garcia MA, Dickstein K, Albuquerque A, Conthe P, et al.: Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005, 26:384-416.
• [5]Silver MA, Horton DP, Ghali JK, Elkayam U: Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 2002, 39:798-803.
• [6]Burger AJ, Elkayam U, Neibaur MT, Haught H, Ghali J, Horton DP, Aronson D: Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol 2001, 88:35-39.
• [7]Burger AJ, Horton DP, LeJemtel T, Ghali JK, Torre G, Dennish G, Koren M, Dinerman J, Silver M, Cheng ML, Elkayam U: Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 2002, 144:1102-1108.
• [8]Guglin M, Hourani R, Pitta S: Factors determining extreme brain natriuretic peptide elevation. Congest Heart Fail 2007, 13:136-141.
• [9]Law C, Glover C, Benson K, Guglin M: Extremely high brain natriuretic peptide does not reflect the severity of heart failure. Congest Heart Fail 2010, 16:221-225.
• [10]Nakajima-Takenaka C, Sakata S, Kato S, Ohga Y, Murata KY, Taniguchi S: Detrimental effects after dobutamine infusion on rat left ventricular function: mechanical work and energetics. Exp Physiol 2005, 90:635-644.
• [11]Ruffolo RR Jr: The pharmacology of dobutamine. Am J Med Sci 1987, 294:244-248.
• [12]Michaels AD, Klein A, Madden JA, Chatterjee K: Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation 2003, 107:2697-2701.
• [13]Omland T, Hagve TA: Natriuretic peptides: physiologic and analytic considerations. Heart Fail Clin 2009, 5:471-487.
• [14]Clerico A, Recchia FA, Passino C, Emdin M: Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol 2006, 290:H17-H29.
• [15]Fermepín MR, Vatta MS, Bianciotti LG, Wolovich TJ, Fernández BE: B-Type and C-type natriuretic peptides modify norepinephrine uptake in discrete encephalic nuclei of the rat. Cell Mol Neurobiol 2000, 20:763-771.
• [16]Maisel A: B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what’s next? Circulation 2002, 105:2328-2331.
• [17]Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R, Luchner A, McDonagh T, Mair J, Nieminen M, Francis G: Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 2003, 24:1710-1718.
• [18]Reichert S, Ignaszewski A: Molecular and physiological effects of nesiritide. Can J Cardiol 2008, 24(Suppl B):15B-18B.
• [19]DeWald TA, Hernandez AF: Efficacy and safety of nesiritide in patients with acute decompensated heart failure. Expert Rev Cardiovasc Ther 2010, 8:159-169.
• [20]Cohen-Solal A, Logeart D, Huang B, Cai D, Nieminen MS, Mebazaa A: Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol 2009, 53:2343-2348.
• [21]Valle R, Aspromonte N, Giovinazzo P, Carbonieri E, Chiatto M, di Tano G, Feola M, Milli M, Fontebasso A, Barro S, Bardellotto S, Milani L: B-type natriuretic Peptide-guided treatment for predicting outcome in patients hospitalized in sub-intensive care unit with acute heart failure. J Card Fail 2008, 14:219-224.
• [22]Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, Clopton P, Maisel A: A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001, 37:386-391.
• [23]Benvenga S: What is the pathogenesis of hyponatremia after subarachnoid hemorrhage? Nat Clin Pract Endocrinol Metab 2006, 2:608-609.
• [24]Clerico A: Pathophysiological and clinical relevance of circulating levels of cardiac natriuretic hormones: is their assay merely a marker of cardiac disease? Clin Chem Lab Med 2002, 40:752-760.